Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 10/20 | 0.43 |
| ▸ | MGAM | O43451 | 9/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 9/20 | 0.43 |
| ▸ | SI | P14410 | 9/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 9/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395074 | 0.70 | KCNMA1 (0.49) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL16882633 | 0.69 | ALDH1A1 (0.51) | GLATHRBGAAMGAMAMY1A | |
| SCHEMBL25022126 | 0.69 | GAA (0.49) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL3936368 | 0.69 | CA12 (0.54) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL9586148 | 0.68 | KCNMA1 (0.54) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL16404988 | 0.67 | KCNMA1 (0.45) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL23840194 | 0.66 | KCNMA1 (0.64) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL12204501 | 0.65 | SLC9A1 (0.53) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL8151358 | 0.65 | SMN1; SMN2 (0.47) | GAAMGAMAMY1ASIMGAM2 | |
| SCHEMBL19092972 | 0.64 | KCNMA1 (0.61) | GAAMGAMAMY1ASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272982-A1 | Method for treatment of prostate cancer and diagnosing of patients benefiting from the same | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2011-01-12 | — | — | EP | disclosed |
| US-20100215638-A1 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215638-A1 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD | ERG, KLK3, ESRRB | GLA 289/4885THRB 2248/4885GAA 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.